SAN DIEGO, Jan. 10, 2022 /PRNewswire/ -- BioAtla, Inc.
(Nasdaq: BCAB), a global clinical-stage biotechnology company
focused on the development of Conditionally Active Biologic (CAB)
antibody therapeutics, today announced that it has entered into a
clinical collaboration with Bristol Myers Squibb (NYSE: BMY) to
investigate BioAtla's two lead CAB-ADC candidates, BA3011 and
BA3021, in combination with Bristol Myers Squibb's anti-PD-1
therapy Opdivo® (nivolumab).
Under the terms of the agreement, BioAtla and Bristol Myers
Squibb will collaborate on clinical trials of separate combination
therapies using two of BioAtla's Conditionally Active Biologic
Antibody Drug Conjugates, BA3011 and BA3021, each in combination
with Opdvio. BioAtla will serve as the study sponsor and
will be responsible for costs associated with the trial execution.
Bristol Myers Squibb will provide
Opdivo clinical drug supply for the
study.
BA3011 (CAB-AXL-ADC) and BA3021 (CAB-ROR2-ADC) are CAB antibody
drug conjugates that target receptor tyrosine kinase AXL and ROR2,
respectively. AXL and ROR2 are important targets as they are
expressed in many solid tumors with higher frequency of expression
observed in tumors previously treated with anti-PD-1 therapy. This,
coupled with the therapeutic index advantages provided by BioAtla's
proprietary CAB technology, lends strong rationale for
investigating BA3011 and BA3021 in combination with
Opdivo.
"BioAtla is very pleased to enter into this collaboration with
Bristol Myers Squibb. Identification of optimal combination
regimens holds significant promise for cancer patients, and we look
forward to expanding investigation of our CAB-ADCs in combination
with Opdivo," stated Jay M.
Short, Ph.D., Chairman, Chief Executive Officer and
co-founder of BioAtla, Inc.
"This collaboration supports our strategy to aggressively drive
development of therapeutics in areas of high unmet medical need and
underscores the potential broad applicability of our CABADCs to
provide benefit to many patients across a wide range of tumor
types," added Scott Smith, President
of BioAtla.
Opdivo® is a trademark of Bristol-Myers Squibb
Company.
About Mecbotamab Vedotin (BA3011)
BA3011,
CAB-AXL-ADC, is a CAB antibody drug conjugate targeting the
receptor tyrosine kinase AXL that is overexpressed across multiple
different solid tumors. We are developing BA3011 as a potential
therapeutic for multiple solid tumor types, including soft tissue
and bone sarcoma, nonsmall cell lung cancer (NSCLC) and ovarian
cancer, with other potential indications in the future. We are
enrolling a potentially registration-enabling Phase 2 clinical
trial (NCT03425279) of BA3011 given as monotherapy or in
combination with a PD-1 inhibitor in soft tissue and primary bone
sarcoma patients 12 years and older that are high AXL tumor
membrane expressors (AXL high). We also are conducting a
Phase 2 study (NCT04681131) in AXL high NSCLC patients who have
previously progressed on PD-1/L1, EGFR, or ALK inhibitor therapy.
In addition, a multicenter investigator-initiated Phase 2 clinical
trial of BA3011 in combination with a PD-1 inhibitor in patients
with platinum-resistant ovarian cancer has been initiated in
Canada and in the US
(NCT04918186).
About Ozuriftamab Vedotin (BA3021)
BA3021,
CAB-ROR2-ADC, is a conditionally and reversibly active antibody
drug conjugate directed against ROR2, a receptor tyrosine kinase
that is overexpressed across many different solid tumors including
lung, head and neck, melanoma, and breast. We are developing BA3021
as a potential therapeutic for multiple solid tumor types,
including NSCLC, melanoma, squamous cell cancer of the head and
neck (SCCHN) and ovarian cancer. We are enrolling a Phase 2 trial
(NCT03504488) of BA3021 monotherapy or in combination with a PD-1
inhibitor in patients with ROR2 high melanoma who have previously
progressed on PD-1/L1 inhibitor and patients with ROR2 high NSCLC
who have previously progressed on PD-1/L1, EGFR or ALK inhibitor
therapy. A Phase 2 study in patients with ROR2 high SCCHN will be
initiated in early 2022. In addition, a multi-center
investigator-initiated Phase 2 clinical trial of BA3021 in
combination with a PD-1 inhibitor in patients with
platinum-resistant ovarian cancer has been initiated in
Canada and in the US
(NCT04918186).
About BioAtla, Inc.
BioAtla is a global
clinical-stage biotechnology company with operations in
San Diego, California, and in
Beijing, China through our
contractual relationship with BioDuro-Sundia, a provider of
preclinical development services. Utilizing its proprietary
Conditionally Active Biologics (CAB) technology, BioAtla develops
novel, reversibly active monoclonal antibody and other protein
therapeutic product candidates. CAB product candidates are designed
to have more selective targeting, greater efficacy with lower
toxicity, and more cost-efficient and predictable manufacturing
than traditional antibodies. BioAtla has extensive and worldwide
patent coverage for its CAB technology and products with more than
500 patents, more than 250 of which are issued. Broad patent
coverage in all major markets include methods of making, screening
and manufacturing CAB product candidates in a wide range of formats
and composition of matter coverage for specific products. BioAtla
has two first-in-class CAB programs currently in Phase 2 clinical
testing in the United States,
mecbotamab vedotin, BA3011, a novel conditionally active
AXL-targeted antibody-drug conjugate (CAB-AXL-ADC), and ozuriftamab
vedotin, BA3021, a novel conditionally active ROR2-targeted
antibody-drug conjugate (CAB-ROR2-ADC). To learn more about
BioAtla, Inc. visit www.bioatla.com.
Forward-looking statements
Statements in this press
release contain "forward-looking statements" that are subject to
substantial risks and uncertainties. Forward-looking statements
contained in this press release may be identified by the use of
words such as "anticipate," "expect," "believe," "will," "may,"
"should," "estimate," "project," "outlook," "forecast" or other
similar words. Examples of forwardlooking statements include, among
others, statements we make regarding our business plans and
prospects, expectations about the sufficiency of our cash and cash
equivalents, expected R&D and G&A expenses, the timing and
success of our clinical trials and related data, and plans to
advance development of several bispecific CAB candidates, including
the timing of potential IND submissions. Forward-looking statements
are based on BioAtla's current expectations and are subject to
inherent uncertainties, risks and assumptions, many of which are
beyond our control, difficult to predict and could cause actual
results to differ materially from what we expect. Further, certain
forward-looking statements are based on assumptions as to future
events that may not prove to be accurate. Factors that could cause
actual results to differ include, among others: potential delays in
clinical and pre-clinical trials due to the global COVID-19
pandemic; other potential adverse impacts due to the global
COVID-19 pandemic such as delays in regulatory review,
manufacturing and supply chain interruptions, adverse effects on
healthcare systems and disruption of the global economy; our
dependence on the success of our CAB technology platform; our
ability to enroll patients in our ongoing and future clinical
trials; the success of our current and future collaborations with
third parties; our reliance on third parties for the manufacture
and supply of our product candidates for clinical trials; our
reliance on third parties to conduct our clinical trials and some
aspects of our research and preclinical testing; and those other
risks and uncertainties described in the section titled "Risk
Factors" in our Annual Report on Form 10-K filed with the
Securities and Exchange Commission (SEC) on March 24, 2021 and in our Quarterly Reports on
Form 10-Q filed with the SEC on May 12,
2021, August 13, 2021, and
November 15, 2021 and other reports
as filed with the SEC. Forward-looking statements contained in this
press release are made as of this date, and BioAtla undertakes no
duty to update such information except as required under applicable
law.
Contact:
Richard Waldron
Chief Financial Officer
BioAtla, Inc.
rwaldron@bioatla.com
858.356.8945
View original content to download
multimedia:https://www.prnewswire.com/news-releases/bioatla-announces-clinical-collaboration-with-bristol-myers-squibb-to-study-mecbotamab-vedotin-ba3011-and-ozuriftamab-vedotin-ba3021-in-combination-with-opdivo-nivolumab-for-treatment-of-solid-tumors-301457475.html
SOURCE BioAtla, Inc.